Sagar D Sardesai, MBBS

Sagar D Sardesai, MBBS

Physician

4.8 out of 5

Specialty:Medical Oncology

Gender: Male

Languages: Hindi

Academic Title: Associate Professor in the College of Medicine

Research Program: Cancer Control

  • About Me

    I am a breast medical oncologist and researcher who joined the Division of Medical Oncology at The Ohio State University in 2016 after completing my fellowship training in hematology and oncology at Indiana University (IU). I have a proven track record of academic and clinical excellence. I earned my medical degree in Mumbai, India and my master’s degree in public health at The University of Texas Health Science Center in Houston. I then completed a general internal medicine internship at the University of Buffalo School of Medicine – State University of New York before embarking on my fellowship training at IU. I am a member of the Cancer Control Program at the OSUCCC – James. My research involves identifying predictive biomarkers in BRCA gene-mutated tumors and triple-negative breast cancers. I also have research interests in women who are at high risk for breast and ovarian cancers, and in the correlation between breast density and obesity in healthy women. I currently serve as the co-medical director of the high-risk breast program. Additionally, I have published manuscripts in scientific journals and presented original articles at national conferences. I am a reviewer for multiple medical journals and a member of several medical organizations, including the American Society of Clinical Oncology, American College of Hematology and American Medical Association. Working at the OSUCCC – James gives me the resources and technology to provide the best care possible to my patients. I try and educate each patient about their condition, so they can make active decisions regarding treatment. At The James, we define cancer by its biologic and genetic makeup, knowing that it’s different in each person. Through collaboration and cutting-edge technology, we create improved outcomes, faster responses, fewer side effects and more hope for cancer patients.

  • Clinical Expertise

    • Ovarian Cancers
    • Genes, BRCA1
    • Genes, BRCA2
    • Breast Cancer
  • Where I See Patients

    Stefanie Spielman Comprehensive Breast Center

    Stefanie Spielman Comprehensive Breast Center

    Location Information
  • Education & Training

    Fellowship - Hematology & Oncology

    • Indiana University Hospital
      550 University Blvd, Indianapolis, IN

    Internship - Internal Medicine

    • State University of NY Health Science Center/Brooklyn
      PO Box 30046, Brooklyn, NY

    Residency - Internal Medicine

    • State University of NY Health Science Center/Brooklyn
      PO Box 30046, Brooklyn, NY

    Medical School

    • Topiwala National Medical College
      Maharashtra University of Health Sciences, Mumbai

    Graduate - Epidemiology

    • University of Texas HSC School of Public Health
      PO Box 20186, Houston, TX
  • Academic Office & Contact Information

    Academic Office:

    Lincoln Tower 1335
    1800 Cannon Dr
    Columbus, Ohio 43210

  • Reviews

    Patient Satisfaction Review

    The overall patient satisfaction rating is an average of all patient responses to the five questions gathered from the Outpatient Oncology survey, developed by Press Ganey Associates for use in oncology clinics across the country. On behalf of The James, Press Ganey administers the survey to patients who see our providers in an outpatient clinic office. For additional information about the patient satisfaction survey, please visit our Patient Satisfaction Survey page

    The comments are submitted by patients and reflect their view and opinions. The comments are not endorsed by and do not necessarily reflect the views of The James.

    4.8 out of 5 overall

    Kept you informed about your condition and treatment
    4.8 / 5
    Amount of time spent with you
    4.7 / 5
    Concern for your questions and issues
    4.8 / 5
    Skill and knowledge
    4.8 / 5
    Overall quality of care
    4.8 / 5

    Patient Comments

    Reviewed on January 14, 2025

    I can't believe--and neither can friends--how much time I get for an appointment. Such care and concern. I have been blessed with Dr. Sardesai and Jaimie and staff.

    Reviewed on January 11, 2025

    Excellent doctor very kind and compassionate

    Reviewed on January 10, 2025

    He is an excellent oncologist!

    Reviewed on December 13, 2024

    Dr Sardesi is the best. He answers all my concerns.

    Reviewed on December 6, 2024

    I love Dr. Sardesai. I'm praying Anthem can come to an ageeement

    Reviewed on October 28, 2024

    Dr S was kind, informative and caring.

    Reviewed on September 20, 2024

    I was given all the time I needed for my questions. I was meet with great compassion and care. Additional evidence bases information was provided to allow meTo be more informed about future concern and risk factors. Dr S is top notch!!!!!

    Reviewed on September 15, 2024

    My doctor is an excellent caregiver.

    Reviewed on September 9, 2024

    I have always felt that good attention is provided and I never feel rushed.

    Reviewed on August 25, 2024

    Excellent and thorough care.

    Reviewed on July 31, 2024

    Was very impressed with the variety of topics addressed and what to expect as far as the next step. Dr. Sardesai was very knowledgeable and personable. He also took the time to listen and to ask if I had any questions or concerns along the way.

    Reviewed on July 23, 2024

    Best doctor evier

    Reviewed on July 1, 2024

    I deeply value the care and concern Dr Sardesai has for me and his other patients. He takes his time with me, answers my questions and remembers my issues and questions from previous visits. This is greatly appreciated.

    Reviewed on June 25, 2024

    We were so impressed and comforted with our visit with Dr. Sardesai!. Not only Is he extremely knowledgeable, made it easy to understand but his positivity and compassion made us come out feeling better than we've felt in weeks!

    Reviewed on April 22, 2024

    Only my first visit but I was very impressed with staff

    Reviewed on April 7, 2024

    Always great

    Reviewed on March 25, 2024

    I have had good care with Dr Sardesai.My former doctor resigned.I drive 65 miles each way. Sometimes it is a long day.I have had no treatments. I take a pill and tumor is gone, thankfully.I am very pleased.

    Reviewed on February 10, 2024

    The Dr was very nice, took his time and explained everything!

    Reviewed on February 9, 2024

    Very thorough in answering all my questions in an honest and easy to understand manner.

    Reviewed on January 22, 2024

    Never close to being on time

    Reviewed on January 15, 2024

    Dr. Sardesai and his team always put the patient first

    Reviewed on December 18, 2023

    Always answers my questions about whatever I'm concerned about

    Reviewed on November 24, 2023

    Never have I been treated so good and was kept informed during stay. Best health care ever.

    Reviewed on November 22, 2023

    Was very much concerned and helpful.

    Reviewed on November 15, 2023

    I have been a patient here for over 6 years. The staff is informative, kind and courteous.

    Reviewed on October 25, 2023

    Dr Sardesai never rushes you and always answers all questions. And provides good information on questions.

    Reviewed on October 18, 2023

    Excellent caregivers

  • Videos

  • Publications

    September 12, 2024

    Association Between Inflammatory Dietary Pattern and Mammographic Features.

    Azam S, Asad S, Chitnis SD, Collier KA, Kensler KH, Sudheendra P, Pariser A, Romanos-Nanclares A, Eliassen AH, Sardesai S, Heine J, Tabung FK, Tamimi RM, Stover DG

    J Nutr

    June 19, 2024

    The survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancer.

    Johnson KCC, Ni A, Quiroga D, Pariser AC, Sudheendra PK, Williams NO, Sardesai SD, Cherian M, Stover DG, Gatti-Mays M, Ramaswamy B, Lustberg M, Jhawar S, Skoracki R, Wesolowski R

    NPJ Breast Cancer

    June 1, 2024

    Real-world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer.

    Sukumar JS, Sardesai S, Ni A, Williams N, Johnson K, Quiroga D, Ramaswamy B, Wesolowski R, Cherian M, Stover DG, Gatti-Mays M, Pariser A, Sudheendra P, George MA, Lustberg M

    Cancer Med

    May 30, 2024

    Chemotherapy-induced gut microbiome disruption, inflammation, and cognitive decline in female patients with breast cancer.

    Otto-Dobos LD, Grant CV, Lahoud AA, Wilcox OR, Strehle LD, Loman BR, Adarkwah Yiadom S, Seng MM, Halloy N, Russart KLG, Carpenter KM, Dawson E, Sardesai SD, Williams NO, Gatti-Mays ME, Stover DG, Sudheendra PK, Wesolowski R, Kiecolt-Glaser JK, Bailey MT, Andridge RR, Pyter LM

    Brain Behav Immun

    November 22, 2023

    Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in breast cancer patients.

    Minta A, Rose L, Park C, Ramaswamy B, Stover D, Gatti-Mays M, Cherian M, Williams N, Sudheendra P, Wesolowski R, Sardesai S, Lustberg M, Loprinzi CL, Ruddy KJ, Cathcart-Rake E, Trovato S, Dulmage B

    Support Care Cancer

    October 14, 2023

    Survival outcomes seen with neoadjuvant chemotherapy in the management of locally advanced inflammatory breast cancer (IBC) versus matched controls.

    Johnson KC, Grimm M, Sukumar J, Schnell PM, Park KU, Stover DG, Jhawar SR, Gatti-Mays M, Wesolowski R, Williams N, Sardesai S, Pariser A, Sudheendra P, Tozbikian G, Ramaswamy B, Doto D, Cherian MA

    Breast

    September 4, 2023

    Depression, Inflammation, and Intestinal Permeability: Associations with Subjective and Objective Cognitive Functioning throughout Breast Cancer Survivorship.

    Madison AA, Andridge R, Kantaras AH, Renna ME, Bennett JM, Alfano CM, Povoski SP, Agnese DM, Lustberg M, Wesolowski R, Carson WE, Williams NO, Reinbolt RE, Sardesai SD, Noonan AM, Stover DG, Cherian MA, Malarkey WB, Kiecolt-Glaser JK

    Cancers (Basel)

    June 24, 2023

    The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer.

    Johnson KCC, Goldstein D, Tharakan J, Quiroga D, Kassem M, Grimm M, Miah A, Vargo C, Berger M, Sudheendra P, Pariser A, Gatti-Mays ME, Williams N, Stover D, Sardesai S, Wesolowski R, Ramaswamy B, Tozbikian G, Schnell PM, Cherian MA

    Oncol Ther

    March 14, 2023

    Hyperinsulinemic and Pro-Inflammatory Dietary Patterns and Metabolomic Profiles Are Associated with Increased Risk of Total and Site-Specific Cancers among Postmenopausal Women.

    Jin Q, Shi N, Lee DH, Rexrode KM, Manson JE, Balasubramanian R, Zhang X, Neuhouser ML, Lopez-Pentecost M, Thomson CA, Zick SM, Felix AS, Stover DG, Sardesai SD, Esnakula A, Mo X, Clinton SK, Tabung FK

    Cancers (Basel)

    January 1, 2023

    Phase Ib study of HSP90 inhibitor, onalespib (AT13387), in combination with paclitaxel in patients with advanced triple-negative breast cancer.

    Williams NO, Quiroga D, Johnson C, Brufsky A, Chambers M, Bhattacharya S, Patterson M, Sardesai SD, Stover D, Lustberg M, Noonan AM, Cherian M, Bystry DM, Hill KL, Chen M, Phelps MA, Grever M, Stephens JA, Ramaswamy B, Carson WE, Wesolowski R

    Ther Adv Med Oncol

    November 14, 2022

    Association of body mass index and inflammatory dietary pattern with breast cancer pathologic and genomic immunophenotype in the nurses' health study.

    Asad S, Damicis A, Heng YJ, Kananen K, Collier KA, Adams EJ, Kensler KH, Baker GM, Wesolowski R, Sardesai S, Gatti-Mays M, Ramaswamy B, Eliassen AH, Hankinson SE, Tabung FK, Tamimi RM, Stover DG

    Breast Cancer Res

    October 5, 2022

    Typhoid Vaccine Does Not Impact Feelings of Social Connection or Social Behavior in a Randomized Crossover Trial Among Middle-Aged Female Breast Cancer Survivors.

    Madison AA, Way B, Ratner K, Renna M, Andridge R, Peng J, Rosie Shrout M, Sheridan J, Lustberg M, Ramaswamy B, Wesolowski R, VanDeusen JB, Williams NO, Sardesai SD, Noonan AM, Reinbolt RE, Stover DG, Cherian MA, Malarkey WB, Kiecolt-Glaser JK

    Brain Behav Immun

    July 13, 2022

    Distress Disorder Histories Relate to Greater Physical Symptoms Among Breast Cancer Patients and Survivors: Findings Across the Cancer Trajectory.

    Renna ME, Shrout MR, Madison AA, Lustberg M, Povoski SP, Agnese DM, Reinbolt RE, Wesolowski R, Williams NO, Ramaswamy B, Sardesai SD, Noonan AM, VanDeusen JB, Stover DG, Cherian M, Malarkey WB, Di Gregorio M, Kiecolt-Glaser JK

    Int J Behav Med

    July 10, 2022

    Living with Advanced Breast Cancer: A Descriptive Analysis of Survivorship Strategies.

    Grimm M, Radcliff L, Giles M, Nash R, Holley E, Panda S, Brophy L, Williams N, Cherian M, Stover D, Gatti-Mays ME, Wesolowski R, Sardesai S, Sudheendra P, Reinbolt R, Ramaswamy B, Pariser A

    J Clin Med

    May 11, 2022

    Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.

    O'Shaughnessy J, Brufsky A, Rugo HS, Tolaney SM, Punie K, Sardesai S, Hamilton E, Loirat D, Traina T, Leon-Ferre R, Hurvitz SA, Kalinsky K, Bardia A, Henry S, Mayer I, Zhu Y, Phan S, Cortés J

    Breast Cancer Res Treat

    April 1, 2022

    Breast cancer survivors' typhoid vaccine responses: Chemotherapy, obesity, and fitness make a difference.

    Kiecolt-Glaser JK, Renna M, Peng J, Sheridan J, Lustberg M, Ramaswamy B, Wesolowski R, VanDeusen JB, Williams NO, Sardesai SD, Noonan AM, Reinbolt RE, Stover DG, Cherian MA, Malarkey WB, Andridge R

    Brain Behav Immun

    February 23, 2022

    Delay Discounting as a Potential Therapeutic Target for Weight Loss in Breast Cancer Survivors.

    Sukumar JS, Vaughn JE, Tegge A, Sardesai S, Lustberg M, Stein J

    Cancers (Basel)

    January 31, 2022

    Long-Term Follow-Up of Fractional CO2 Laser Therapy for Genitourinary Syndrome of Menopause in Breast Cancer Survivors.

    Quick AM, Hundley A, Evans C, Stephens JA, Ramaswamy B, Reinbolt RE, Noonan AM, Van Deusen JB, Wesolowski R, Stover DG, Williams NO, Sardesai SD, Faubion SS, Loprinzi CL, Lustberg MB

    J Clin Med

    January 1, 2022

    Activity of Estrogen Receptor β Agonists in Therapy-Resistant Estrogen Receptor-Positive Breast Cancer.

    Datta J, Willingham N, Manouchehri JM, Schnell P, Sheth M, David JJ, Kassem M, Wilson TA, Radomska HS, Coss CC, Bennett CE, Ganju RK, Sardesai SD, Lustberg M, Ramaswamy B, Stover DG, Cherian MA

    Front Oncol

    November 1, 2021

    Inhibiting Fatty Acid Synthase with Omeprazole to Improve Efficacy of Neoadjuvant Chemotherapy in Patients with Operable TNBC.

    Sardesai SD, Thomas A, Gallagher C, Lynce F, Ottaviano YL, Ballinger TJ, Schneider BP, Storniolo AM, Bauchle A, Althouse SK, Perkins SM, Masters AR, Stratford RE, Dong Z, Liu JY, Zhang JT, Miller KD

    Clin Cancer Res

    October 1, 2021

    Assessment of Leptomeningeal Carcinomatosis Diagnosis, Management and Outcomes in Patients with Solid Tumors Over a Decade of Experience.

    Rinehardt H, Kassem M, Morgan E, Palettas M, Stephens JA, Suresh A, Ganju A, Lustberg M, Wesolowski R, Sardesai S, Stover D, Vandeusen J, Cherian M, Prieto Eibl MDPG, Miah A, Alnahhas I, Giglio P, Puduvalli VK, Ramaswamy B, Williams N, Noonan AM

    Adv Psychosom Med

    September 1, 2021

    Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.

    Bardia A, Tolaney SM, Punie K, Loirat D, Oliveira M, Kalinsky K, Zelnak A, Aftimos P, Dalenc F, Sardesai S, Hamilton E, Sharma P, Recalde S, Gil EC, Traina T, O'Shaughnessy J, Cortes J, Tsai M, Vahdat L, Diéras V, Carey LA, Rugo HS, Goldenberg DM, Hong Q, Olivo M, Itri LM, Hurvitz SA

    Ann Oncol

    April 22, 2021

    Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.

    Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortés J, O'Shaughnessy J, Diéras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS, ASCENT Clinical Trial Investigators

    N Engl J Med

    January 1, 2021

    A Cardiac Rehabilitation Program for Breast Cancer Survivors: A Feasibility Study.

    Zvinovski F, Stephens JA, Ramaswamy B, Reinbolt RE, Noonan AM, VanDeusen JB, Wesolowski R, Stover DG, Williams NO, Sardesai SD, Mehta L, Foraker R, Gulati M, Lustberg M, Quick AM

    J Oncol

  • Consulting and Related Relationships

    At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 09/30/2024, Dr. Sardesai has reported relationships with the companies or entities listed below. If you have questions about the relationships listed below, please ask the faculty member. If you have questions about how these relationships are monitored by The Ohio State University Wexner Medical Center, please contact our Compliance Office.

    • AstraZeneca
    • Gilead Sciences
    • Stemline Therapeutics